[mchakravarti7]

Hi Michael, thanks for the AMA. When you evaluate an early stage biotech startup, what would you say is the most important thing that you look for? - clinically validated products, or a solid long term business model?

With Trump picking Scott Gottlieb to be the next FDA commissioner, the FDA approval process is expected to get more lenient. Would you say that YC (or investors in general) would be open to take more risks with high tech startups that do not have a clinically validated product as of now?

One more question - Given that the FDA process takes a lot of time, quite a few biotech companies often get acquired or merged with bigger companies that can afford to do so, without ever having actually gotten their product out on the market. Would you say that you look at the company's potential return in that sense when you evaluate startups? I'm not entirely sure if this question makes sense, so let me know if you want me to clarify!